Welcome to our book review site go-pdf.online!
You may have to Search all our reviewed books and magazines, click the sign up button below to create a free account.
Renal Cell Carcinoma
Renal cell carcinoma represents a heterogeneous group of tumors, the most common of which is clear cell adenocarcinoma. The annual incidence of this tumor appears to be rising and approximately 12,000 individuals die from this cancer annually in the United States. One third of patients who present have metastatic disease at the time of diagnosis, and another 40% who undergo nephrectomy will ultimately develop this complication. Over the past 10 years, a significant amount of new information concerning the epidemiology, mole- lar and immunologic characteristics, and therapy for patients with these tumors has appeared. The recognition that inherited forms of renal cancer exist, and that chromo...
Intraperitoneal Cancer Therapy
This book investigates intraperitoneal chemotherapy in a variety of complex and interesting ways. The volume details major clinical trails to date. Authors also examine regional approaches to therapy, systemic therapy, and the use of carboplatin and paclitaxel as the standard treatment for women with stages III and IV ovarian cancer. The future direction of intraperitoneal chemotherapy both normothermic and hyperthermic is also covered.
Renal Cell Carcinoma
In the second edition of their critically acclaimed book, Ronald Bukowski, Robert Motzer, and Robert Figlin have thoroughly updated and expanded their survey of clinical, biological and pathological management of localized and advanced renal cell carcinoma. A panel of internationally renowned contributors explores the latest developments in molecular genetics, focusing on the novel targets that have been discovered in epithelial renal tumors. The discussion includes the specific biology of selected target molecules or receptors and the various agents that inhibit these targets, including full chapters devoted to drugs that selectively inhibit receptor tyrosine kinases, such as sunitinib and axitinib. Further attention is paid to leading-edge strategies that target and inhibit tumor associated angiogenesis and block the vascular endothelial growth factor pathway. Comprehensive and authoritative, Renal Cell Carcinoma: Molecular Targets and Clinical Applications, Second Edition is the definitive text on the rapidly evolving landscape of experimental therapeutics, written and edited by the pioneers of the field.
Inflammation and Cancer
This volume examines in detail the role of chronic inflammatory processes in the development of several types of cancer. Leading experts describe the latest results of molecular and cellular research on infection, cancer-related inflammation and tumorigenesis. Further, the clinical significance of these findings in preventing cancer progression and approaches to treating the diseases are discussed. Individual chapters cover cancer of the lung, colon, breast, brain, head and neck, pancreas, prostate, bladder, kidney, liver, cervix and skin as well as gastric cancer, sarcoma, lymphoma, leukemia and multiple myeloma.
Cancer Neurology in Clinical Practice
Neuro-oncology has evolved substantially as a clinical and research discipline over the past few decades. Cancer Neurology in Clinical Practice: Neurologic Complications of Cancer and its Treatment, Second Edition provides clinicians from various backgrounds and levels of training with a reference to help focus the differential diagnosis, treatment strategy, and management plan for the cancer patient with neurologic symptoms and findings. The volume begins with an overview of the field of neuro-oncology and a review of the role of neuroimaging in the diagnosis of neuro-oncologic disease. Several chapters on interpretation and management of common neuro-oncologic symptoms follow. Subsequent s...
Signalling Molecules as Targets in Cancer Therapy
This book presents state-of-the-art information on the molecules of cell signalling pathways that represent actual or future targets for cancer therapy. By giving an update of the most promising approaches in this rapidly evolving field, the book contributes to the translation of the recent advances in the knowledge of intracellular signalling into the generation of innovative biomolecules as specific tools to target the most promising tumour-specific candidates. The book begins logically with the molecules first encountered along the signalling pathways, the membrane receptors for growth factors (Part I). Next, Part II presents several examples of intracellular molecular targets that are situated one step beyond in the pathways, while Part III addresses the difficult task of tuning the delicate balance between cell death and survival. In Part IV, the reader is taken into the practical problems raised by the therapy of specific cancers (glioma, childhood leukaemia), and into an original strategy from the field of nuclear medicine with the potential to generate innovative molecular-targeted cancer therapies.
To Act as a Unit
None
